Geographic Atrophy

The newest research findings create "tangible benchmarks" for how earlier treatment can lead to better outcomes, said Dr. Kim.

Maximizing treatment based on GA location, lesion progression, and morphologic retinal changes.

The company can now initiate the Opti-GAIN (Optimized Geographic Atrophy INterventional) phase 1/2 clinical trial.

A recent study reveals that most UK patients with geographic atrophy find intravitreal complement inhibitors acceptable, emphasizing the importance of perceived visual benefits.

Character Biosciences enhances its leadership team and secures $93 million in Series B funding to advance treatments for degenerative eye diseases.

The lesion area growth was reduced by more than 50% in the first human clinical trial of K8.

We ask leading experts in the field what eye disease they would cure and why.

K8 was found to reduce geographic atrophy lesion area growth by more than 50% in its first human clinical trial of the drug.

Belite Bio completes its phase 3 trial for tinlarebant, a potential first treatment for Stargardt disease, with results expected in late 2025.

We ask leading experts in the field what eye disease they would cure and why.

Researchers conducted this study to determine how often and why spontaneous soft drusen regresses without atrophy in patients who had intermediate or atrophic age-related macular degeneration.

Researchers will investigate a gene in the eye that is crucial for normal vision, but can cause retinal diseases when mutated that often lead to blindness.

A new study explores the "drusen ooze" hypothesis, revealing how drusen can regress without atrophy in age-related macular degeneration.

We ask leading experts in the field what eye disease they would cure and why.

An understanding of GA growth kinetics is key to addressing the pathophysiology of age-related macular degeneration.

Fovea-sparing, multifocal, and bilateral lesions exhibited the fastest growth rates.

Kriya is developing gene therapies targeting chronic diseases such as geographic atrophy, trigeminal neuralgia, and type 1 diabetes.

Kriya is developing gene therapies targeting chronic diseases such as geographic atrophy, trigeminal neuralgia, and type 1 diabetes.

Fovea-sparing, multifocal, and bilateral lesions exhibited the fastest growth rates.